















382Carotid endarterectomy for asymptomatic carotid
stenosis in the very elderly
Enzo Ballotta, MD,a Antonio Toniato, MD,a Anna Da Roit, MD,a Renata Lorenzetti, MD,a
Giacomo Piatto, MD,a and Claudio Baracchini, MD,b Padova, Italy
Background: The indication for carotid endarterectomy (CEA) is uncertain in patients with asymptomatic severe ($60%
luminal narrowing according to the North American Symptomatic Carotid Endarterectomy Trial criteria) carotid stenosis
(ASCS), especially in the very elderly, because current evidence suggests that the risk of future stroke has been dropping in
the past two decades owing to the recent advances in medical therapy. The aim of this observational study was to compare
early and late outcomes in patients $80 years old with ASCS treated with CEA plus best medical treatment (BMT) or
with BMT alone.
Methods: From 2005 to 2012, 69 octogenarians with ASCS underwent CEA plus BMT (group 1), and another 54 received
BMT alone (group 2). All operations were eversion CEAs. BMT included lipid-lowering drugs, new antiplatelet and
antihypertensive agents, avoidance of smoking, careful blood pressure and glycemic control, and lifestyle changes. Follow-
up with serial ultrasonographic examination was obtained in 118 patients for a median 4.4-year period.
Results: There were no perioperative (30-day) strokes or deaths and one transient ischemic attack (1.4%). One late minor
stroke developed in a CEA patient (1.5%). No late restenoses or occlusions were detected. Five patients in group 2 (9.6%)
became symptomatic (one transient ischemic attack and four minor strokes) and subsequently underwent successful CEA;
all their carotid plaques were complicated by ulceration and intraplaque hemorrhage (with plaque progression in four
cases), conﬁrmed by computed tomography images. The rate of freedom from cerebral ischemic events at 5 years showed a
signiﬁcant beneﬁt for elderly patients who had CEA vis-à-vis those who did not (98% vs 84%; P[ .04), and so did the 5-
year rate of freedom from ipsilateral carotid disease progression (100% vs 91%; P[ .01). At 5 years, the mortality rate was
comparable for elderly patients whether they had CEA or not (66% vs 68%; P [ .65).
Conclusions: CEA is a safe, effective, and durable treatment for ASCS in patients aged 80 years or more, carrying an
insigniﬁcant perioperative stroke/death risk. CEA associated with BMT seems preferable to BMT alone in preventing the
risk of ipsilateral ischemic events, without translating into a longer survival. (J Vasc Surg 2015;61:382-8.)Asymptomatic carotid artery stenosis with $50%
luminal narrowing is a common ﬁnding in aging individ-
uals, with 7% to 9% of the population affected by the age
of 75 years.1 Large randomized clinical trials (RCTs),
such as the Asymptomatic Carotid Atherosclerotic Study
(ACAS)2 and the Asymptomatic Carotid Surgery Trial
(ACST),3 have demonstrated the therapeutic beneﬁts of
carotid endarterectomy (CEA) over best medical treatment
(BMT) for patients with asymptomatic severe carotid ste-
nosis (ASCS), albeit with a signiﬁcantly lower absolute
beneﬁt than in patients with symptomatic carotid steno-
sis,4,5 mainly because of the low risk of stroke in medically
treated patients. Since the ﬁrst RCTs were conducted, sig-
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lowering drugs such as statins, latest-generation antiplatelet
and antihypertensive drugs, better glycemic control, and
lifestyle changes, so there is now convincing evidence of a
drop in the risk of ischemic cerebrovascular events as a
result.6 This has prompted some authors to conclude that
the previously reported signiﬁcant beneﬁt of CEA over
BMT was due to a suboptimal medical therapy,7 to ques-
tion the appropriateness of CEA for patients with ASCS,
and to suggest that BMT should replace CEA as the stan-
dard of care for such patients.7-9 On the other hand, recent
prospective data from the Reduction of Atherothrombosis
for Continued Health (REACH) registry showed a rela-
tively high incidence of cerebrovascular ischemic events
occurring within 12 months in a large cohort of patients
with ASCS, even though most of them were taking statins
and antihypertensive drugs at baseline.10 In this scenario,
the optimal management for primary prevention of stroke
in patients with ASCS remains controversial. Despite evi-
dence of the incidence of stroke and stroke-related mortal-
ity increasing dramatically with advancing age, and given
that elderly people are typically seen in daily clinical prac-
tice, concern has been voiced about the role of CEA for pa-
tients with ASCS aged 80 years or more because of the
inherent risks of surgery and uncertainty surrounding the
long-term survival of this age group after CEA.11,12
The purpose of this observational study was to analyze
the perioperative (30-day) and long-term outcomes of
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A cohort of patients with ASCS in the same age group who
were treated with BMT alone during the same period
served as a control group.
METHODS
Our Institutional Review Board and Ethics Committee
approved the study. All patients gave their written
informed consent to the analysis of their records and the
publication of the ﬁndings.
Details of all consecutive patients undergoing primary
CEA at our tertiary referral center between 2005 and
2012 for symptomatic and asymptomatic carotid lesionsd
according to the North American Symptomatic Carotid
Endarterectomy Trial (NASCET)4 and the ACAS2 recom-
mendations, respectivelydwere prospectively stored in a
vascular registry. During this period, 384 patients under-
went 444 primary CEAs (60 were bilateral) for symptom-
atic carotid disease, and another 198 patients with ASCS
underwent 228 primary CEAs (30 were bilateral). The reg-
istry was queried to identify patients with ASCS ($60%
luminal narrowing according to the NASCET criteria)
aged 80 years or more who were treated with CEA plus
BMT; this yielded 69 patients who underwent 72 CEAs
(group 1). For the purpose of this study, we also consid-
ered data from the electronic medical records concerning
another 54 patients aged 80 years or more with ASCS
(group 2) who were referred to our institution during
the study period for surgical revascularization but did not
undergo CEA, regardless of comorbidities, because their
carotid lesion was stable (homogeneous isoechoic plaque
with no evidence of ulceration or intraplaque hemorrhage)
on B-mode ultrasound (43 of 54; 79.6%) or because they
refused surgery after being informed of the pros and cons
(16 of 54; 29.6%). None of the patients in group 2 were
refused CEA for a limited life expectancy (<3-5 years).
As in group 1, all group 2 patients were given BMT,
including combination of antiplatelet drugs (aspirin
100 mg/d or clopidogrel 75 mg/d if aspirin was contrain-
dicated), antihypertensive and antidiabetic agents, and
lipid-lowering drugs (atorvastatin 40 or 80 mg/d, aiming
for a low-density lipoprotein level <100 mg/dL); they
were advised not to smoke and to adopt lifestyle changes
as necessary and scheduled for strict clinical and ultrasono-
graphic follow-up.
Patients scheduled for CEA with concomitant coronary
artery bypass grafting or concurrent surgery for associated
supra-aortic trunk lesions were excluded from the present
analysis. All patients’ demographic and clinical data were
recorded on a standardized form, including potential
atherosclerotic risk factors, anatomic and clinical variables,
preoperative medication, details of surgery, and all periop-
erative outcomes. For most patients, the diagnosis of
carotid disease was based on preoperative duplex ultra-
sound scans, combined with magnetic resonance angiog-
raphy, computed tomography (CT) angiography, or
digital subtraction angiography in selected patients (ie,
those who had either a pseudo-occlusion on duplexultrasound or a stenosis of the carotid intracranial segment
detected by transcranial color-coded Doppler sonography
that was performed routinely in all patients of both
groups). The velocity criteria and the plaque’s morphology
were taken into account for CEA decision-making pur-
poses. As described elsewhere,13 a peak systolic velocity
(PSV) >140 cm/s with spectral broadening throughout
systole and an increased end-diastolic velocity were consis-
tent with a stenosis with a $50% reduction in diameter,
whereas a PSV >210 cm/s and an end-diastolic velocity
between 110 and 140 cm/s were consistent with a
$70% stenosis. The 60% stenosis criterion was PSVstenosis/
PSVpre-stenosis ¼ 3; for 50% stenosis, this rate was 2; and for
70% stenosis, this rate was 4. All patients of the two groups
underwent neurologic assessment by the consultant
neurologist on presentation, on awakening from the anes-
thesia, before discharge from the hospital, and during the
follow-up. Statins were administered to all patients with
diabetes, dyslipidemia, or extracranial or intracranial artery
stenosis; antiplatelet treatment was considered for all pa-
tients with diabetes, ischemic heart disease, or extracranial
or intracranial or peripheral artery disease. Preoperative
preparation of the patient was standardized. The preopera-
tive cardiac workup was tailored to each individual’s clinical
history, electrocardiographic ﬁndings, and symptoms. Pa-
tients with evidence of clinically important coronary artery
disease underwent echocardiography or dipyridamole-
thallium stress tests followed by coronary arteriography,
as indicated.
All surgical procedures were eversion CEAs performed
by the same surgeon in patients under general anesthesia
and with routine intraoperative electroencephalographic
monitoring for a selective use of intraluminal shunting.
Speciﬁc perioperative and postoperative phases of the surgi-
cal procedure, including technical details of the CEA, have
been reported elsewhere.14,15
Surveillance protocol. After discharge, visiting nurses
monitored the surgical patients’ blood pressure and neuro-
logic status. All patients of the two groups were scheduled
for regular clinical checkups after 1, 6, and 12 months and
then every 6 months during the follow-up. At each visit,
patients systematically underwent physical and neurologic
assessment by a consultant neurologist and had concomi-
tant duplex ultrasound scans performed by two experi-
enced neurosonographers. All examinations of the two
groups were performed with a high-resolution, color-
coded duplex sonography scanner (the Acuson Sequoia
512 ultrasound system [Siemens Medical Solutions USA,
Inc, Malvern, Pa] up until 2008 and the Philips iU 22
[Philips Healthcare, Bothell, Wash] from 2008 onward)
with a high-frequency (5-10 MHz) linear probe. Patients,
families, and physicians were instructed to contact the
neurologist, if possible, or one of the investigators on the
surgical team if they suspected any new neurologic event.
Neurologic events were always classiﬁed by the consultant
neurologist as follows: transient ischemic attack (TIA),
deﬁned as temporary hemispheric symptoms lasting no
more than 24 hours, with complete recovery; amaurosis
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clinical syndrome of rapidly developing signs or symptoms
of focal loss of cerebral function of vascular origin, lasting
more than 24 hours but not leading to any handicap or
signiﬁcant impairment in activities of daily living, rated
as <3 on the modiﬁed Rankin scale16; or major stroke,
deﬁned as a focal neurologic deﬁcit lasting more than
30 days and inducing a change in lifestyle, assessed as 3 to 5
on the modiﬁed Rankin scale. Brain imaging (CT or
magnetic resonance imaging) was performed in all patients
presenting a new neurologic deﬁcit after CEA. Cardiac
complications were classiﬁed by a single cardiologist and
included (1) myocardial infarction with a diagnosis based
on creatine kinase MB levels and electrocardiographic
ﬁndings, (2) pulmonary edema conﬁrmed by chest radi-
ography, (3) documented ventricular ﬁbrillation or primary
cardiac arrest, and (4) new congestive heart failure
requiring a pacemaker. A postoperative electrocardiogram
was routinely obtained in all patients with a history of
coronary artery disease, congestive heart failure, or
arrhythmia (rhythm other than sinus), and cardiac iso-
enzymes were surveyed in all patients who had new
ﬁndings at postoperative electrocardiography. Other com-
plications and events observed during the follow-up were
recorded in accordance with the guidelines of the Ad Hoc
Committee on Reporting Standards for Cerebrovascular
Disease, Society for Vascular Surgery/North American
Chapter of the International Society of Cardiovascular
Surgery.17
Primary end points were perioperative stroke and death
and any ipsilateral ischemic adverse events during the
follow-up. Follow-up ranged from 1 to 80 months (me-
dian, 4.4 years; mean, 5.6 years).
Statistical analysis. The statistical analysis was per-
formed with the SPSS statistical software (version 12.0.1;
SPSS Inc, Chicago, Ill). Patients’ demographic data are
given as medians, means, and ranges; baseline clinical and
diagnostic ﬁndings are given in terms of incidence rates.
Frequencies and categorical data were compared with c2
or Fisher exact test, as appropriate, calculating the odds ra-
tio (OR) with 95% conﬁdence intervals (CIs). The rates of
freedom from any ipsilateral ischemic neurologic event and
from plaque progression and survival rates were calculated
by the Kaplan-Meier method and are reported as “life-ta-
ble” analyses. Signiﬁcance was assumed at P < .05. Several
data items were analyzed vis-à-vis surgical procedures
rather than patients because each perioperative outcome
was correlated with the surgical procedure and because
patients who underwent bilateral CEAs were exposed to
twice the risk of stroke, death, or other complications.
RESULTS
Descriptive analysis. In group 1, 72 CEAs were per-
formed in 69 patients. One patient was scheduled for bilat-
eral CEA at admission, and the carotid with the more
severe stenosis was corrected immediately, the other
4 weeks later; in two other cases, a contralateral CEA was
performed 19 and 22 months after the ﬁrst procedure.Table I shows the baseline characteristics of the study
population and the comparison between the two groups’
variables. Groups 1 and 2 were comparable for all the
variables considered, the type of concomitant medication at
presentation, and the degree of the ipsilateral carotid
stenosis.
Perioperative results. There were no strokes or
deaths; one perioperative TIA (1.4%) developed in the ter-
ritory of the middle cerebral artery contralateral to the side
operated on (Table II). Duplex ultrasound was performed
immediately and showed that the revascularized vessel was
patent, and cerebral CT and magnetic resonance images
were negative for any new ischemic lesion.
Other complications. There was one episode of
arrhythmia that was managed conservatively (1.4%). Other
surgical complications were two nerve injuries (2.8%;
involving a cranial nerve and a cervical nerve) and one
neck hematoma (1.4%) requiring surgical evacuation but
causing no further complications (Table II).
Long-term results. Among the 123 patients consid-
ered in the study, ﬁve (4%) were lost to follow-up,
including three patients (three CEAs) in group 1, so a
complete follow-up was available for 118 patients. In group
1, there was one late minor stroke (ipsilateral to the side
operated on and contralateral to a carotid occlusion that
was probably hemodynamic in nature, judging from the
CT images). No carotid occlusions or restenoses were
detected. In group 2, duplex ultrasound revealed a pro-
gression of the ipsilateral carotid lesion in ﬁve arteries
(9.6%), within a mean 22.4 months (three arteries pro-
gressed from 60% to 69% and two arteries from 70% to
90%). Four of the patients involved (7.7%) developed
ipsilateral neurologic symptoms (one TIA and three minor
strokes), with ultrasonographic features of intraplaque
hemorrhage conﬁrmed by CT images. A sixth patient
experienced an ipsilateral minor stroke 19 months after
enrollment in the study, and duplex ultrasound showed
intraplaque hemorrhage but no plaque progression. The
ﬁve patients who had become symptomatic (9.6%) were all
taking antiplatelet and statin medication at presentation
and when their neurologic event occurred. The consultant
neurologist conﬁrmed their diagnosis, and they underwent
CEA within 2 weeks of the onset of their ischemic event.
The patient with asymptomatic plaque progression (from
70% to 85%) continued on BMT (1.9%) and was moni-
tored periodically with ultrasound.
The 5-year rate of freedom from cerebral ischemic
events showed a signiﬁcant beneﬁt for group 1 compared
with group 2 (98% vs 84%; OR, 0.15; 95% CI, 0.04-
0.88; P ¼ .04; Fig 1), and so did the 5-year rate of freedom
from overall plaque progression (100% vs 79%; OR, 0; 95%
CI, 0.01-0.60; P ¼ .01; Fig 2), with no differences
emerging when plaque progression developed with symp-
toms (100% vs 88%; log-rank test, P ¼ .06) or no symp-
toms (100% vs 91%; log-rank test, P ¼ .12). Table III
shows the compliance with BMT and lifestyle changes in
the two groups. There were 10 late deaths (15.1%) among
patients who underwent CEA and six (11.5%) among those
Table I. Baseline characteristics
Variable Group 1 (n ¼ 69), No. (%) Group 2 (n ¼ 54), No. (%) P value
Mean age (SD); range 84.6 (3.2); 80-96 84.9 (2.8); 80-91 .94
CEA procedure 72 d d
Male sex 53 (76.8) 37 (68.5) .30
Risk factors
Hypertensiona 48 (69.5) 41 (75.9) .43
Smokingb 43 (62.3) 35 (64.8) .77
PAD 26 (37.7) 21 (38.9) .89
Diabetes mellitus 20 (29.0) 17 (31.4) .76
Hyperlipidemiac 28 (40.6) 26 (48.1) .40
Cardiac disease 35 (50.7) 29 (53.7) .74
CKD 5 (7.2) 4 (7.4) .97d
Pulmonary disease 18 (26.1) 12 (22.2) .62
Concomitant medication
Lipid-lowering drug 54 (78.2) 44 (81.5) .66
Atorvastatin 40 mg 38 (55.0) 27 (50.0)
Atorvastatin 80 mg 16 (23.2) 17 (31.5) .35
Aspirin 40 (57.9) 32 (59.2) .88
Clopidogrel 14 (20.3) 13 (24.1) .61
Aspirin þ clopidogrel 4 (5.8) 7 (12.9) .21d
Warfarin 2 (2.9) 1 (1.8) .71d
CCO 6 (8.6) 3 (5.5) .73d
Degree of carotid stenosis
$60%-69% 28 (38.9) 23 (42.6) .67
70%-90% 37 (51.4) 28 (51.8) .96
>90% 7 (9.7) 3 (5.6) .51d
CCO, Contralateral carotid occlusion; CEA, carotid endarterectomy; CKD, chronic kidney disease; PAD, peripheral arterial disease; SD, standard deviation.
aArterial blood pressure >140/90 mm Hg or blood pressure treated with medication.
bCurrent use or cessation within the last 5 years.
cCholesterol >6.5 mmol/L or triglycerides >2.0 mmol/L.
dBy Fisher exact test.
Table II. Perioperative (30-day) results






Cardiac complications 1 (1.4)
Arrhythmia 1 (1.4)
Nerve injury 2 (2.8)
Neck hematoma 1 (1.4)
CEA, Carotid endarterectomy; TIA, transient ischemic attack.
Fig 1. Kaplan-Meier life-table analysis of the rate of freedom from
ipsilateral cerebral ischemic events between groups 1 and 2. CI,
Conﬁdence interval; OR, odds ratio.
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(n ¼ 9; 56.2%; Table IV). At 3 and 5 years, the survival
rates were 75% 6 8.8% and 65.6% 6 9.6% in group 1
and 76.7% 6 8.4% and 68.2% 6 9.8% in group 2 (OR,
1.25; 95% CI, 0.46-3.39; P ¼ .65; Fig 3).
DISCUSSION
Two major RCTs investigated the role of CEA in pa-
tients with ASCS, reporting a combined risk of periopera-
tive stroke and death of 1.5% in the ACAS2 and 3% in
the ACST,3 with a signiﬁcantly lower 5-year stroke risk
for patients who underwent CEA than for those who did
not (5.1% vs 11% in the ACAS2 and 6.4% vs 11.8% in theACST3). The beneﬁt was particularly relevant for patients
younger than 75 years.2,3 In both studies, the absolute
reduction in the stroke risk associated with CEA was
approximately 1% a year, meaning that the beneﬁt was
likely to be substantial only in patients with a longer life
expectancy. On the basis of these ﬁndings, a certain
Fig 2. Kaplan-Meier life-table analysis of the rate of freedom from
ipsilateral carotid disease progression between groups 1 and 2. CI,
Conﬁdence interval; OR, odds ratio.
Table III. Compliance with best medical treatment





n/N (%) P value
Antihypertensive agents 40/48 (83.3) 36/41 (87.8) .55
Diabetes mellitus control 16/20 (80.0) 13/17 (76.5) .79
Lipid-lowering drugs
Atorvastatin 40 mg 32/41 (78.0) 28/33 (84.5) .45
Atorvastatin 80 mg 13/28 (46.4) 10/21 (47.6) .93
Antiplatelet treatment 63/69 (91.3) 50/54 (92.6) .79
Smoking cessation 38/43 (88.4) 32/35 (91.4) .66
Table IV. Causes of late deaths
Cause of death
Group 1
(66 patients), No. (%)
Group 2
(52 patients), No. (%)
Cardiac disease 6 (9) 3 (5.8)
Stroke 0 0
Pancreatitis 0 1 (1.9)
Cancer 1 (1.5) 1 (1.9)
Renal failure 1 (1.5) 0
Unknown 2 (3.0) 1 (1.9)
Total 10 (15.1) 6 (11.5)
Fig 3. Kaplan-Meier life-table analysis of the survival rate between
groups 1 and 2. CI, Conﬁdence interval; OR, odds ratio.
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in people in their 80s, signiﬁcantly curtailing its indication
in such patients. Current generally accepted guidelines
recommend that CEA should be considered only for
elderly people with a life expectancy of at least 3 to 5 years
and evidence suggesting a perioperative stroke and mortal-
ity risk <3%18; otherwise, BMT should be advised. On the
other hand, although age is a signiﬁcant predictor of life ex-
pectancy, the conviction that mortality and functional
decline continue to increase proportionally with increasing
age19 has recently been questioned. The expected yearly
mortality appears to be the same at 90 years old as at
85 years old and even seems to fall by the age of
100 years.20 Noninvasive medical care has achieved a
reduction in the stroke risk for many people, but its efﬁcacy
has not been veriﬁed among high-risk patients with ASCS
who would otherwise be candidates for CEA.21-24
The results of this observational study suggest that (1)
CEA is a safe, effective, and durable procedure for patients
in their 80s with ASCS; (2) for such elderly patients, CEA
is more effective than BMT alone in preventing the risk of
ipsilateral ischemic events, even if this does not extend pa-
tients’ life expectancy. Leaving aside the RCTs on asymp-
tomatic carotid disease, it would be difﬁcult to draw a
useful comparison with other studies because of the paucityof investigations focusing explicitly on the management of
octogenarians with ASCS, but our perioperative ﬁndings
compare favorably with those reported in earlier experi-
ences.25,26 In a series of 2217 CEAs performed during a
12-year period in 1961 patients, there were 334 symptom-
atic and asymptomatic patients (360 CEAs) aged 80 years
or more; there was no difference in the combined periop-
erative stroke/death rate between the octogenarians with
ASCS and younger patients (0.9% vs 1.4%; P ¼ .86),
although the stroke/death rate was higher in the octoge-
narian cohort as a whole (3.1% vs 1.5%; P ¼ .04).25 On
the basis of data from the Carotid Artery Revascularization
and Endarterectomy (CARE) registry, among 2773 pa-
tients aged >70 years with ASCS, the combined outcomes
for stroke, death, and myocardial infarction did not differ
statistically between those >75 years old and
those <75 years old (3.1% vs 2.0%; P ¼ .08), although
mortality was signiﬁcantly higher among the >75-year-
olds (0.7% vs 0%; P ¼ .006).26
At 3 and 5 years, our elderly patients’ mortality rates
were comparable with the ﬁgures reported by others con-
cerning pooled data on symptomatic and asymptomatic
subjects.25,27,28 Although the causes of two late deaths in
our series were not ascertained (so one or both might
have been stroke related), there were no late stroke-
related deaths in our elderly CEA population, so CEA
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fact that the only late ipsilateral ischemic stroke occurred in
a watershed zone would support the efﬁcacy of CEA in
preventing late strokes due to carotid disease but would
imply that CEA cannot prevent all late strokes.
With recent improvements in medical management,
including patient lifestyle changes (avoiding smoking,
monitoring blood pressure and cholesterol) and triple med-
ical therapy (with lipid-lowering, antihypertensive, and an-
tiplatelet drugs), the risk of stroke in patients with ASCS is
reportedly much lower than it was when the ACAS and
ACST were conducted.29,30 This evidence has supported
the opinion that modern BMT alone sufﬁces for ASCS,
reducing the stroke risk to levels that make CEA unjusti-
ﬁed. This conviction comes mainly from two amply cited
meta-analyses7,31 and several prospective population-
based studies,21,23,32-34 none of which tested the efﬁcacy
of CEA plus BMT vs BMT alone in terms of reducing
the risk of stroke, however.24
The 5-year rate of freedom from stroke of 98% in our
octogenarians who underwent CEA plus BMT indicates
that most of them lived the rest of their lives without
experiencing any strokes, whereas the risk of late ipsilat-
eral ischemic cerebral events was statistically higher in
their medically managed counterparts, even though
more than 80% of them were taking statins and 98%
were receiving antiplatelet/antithrombotic medication.
This ﬁnding is supported by the 5.7% incidence of cere-
brovascular ischemic events at 1 year in a large cohort of
patients with ASCS (mean age, 71.3 6 9.5 years), 70%
of them receiving statins and 87% receiving antihyperten-
sive drugs at baseline.10 In another large study on 900 ca-
rotid arteries with moderate (50%-69%) asymptomatic
carotid lesions, 11% of patients developed an ipsilateral
ischemic event with a 58% incidence of stroke during a
mean follow-up of 3.6 years, despite 86.5% of them taking
antiplatelet agents and 87% of them taking lipid-lowering
drugs.35 Among the patients who became symptomatic,
40% showed a progression of the plaque (from moderate
to severe), but no data are available on the plaque’s
morphology.35 In our series, plaque progression was iden-
tiﬁed in four of the ﬁve patients in group 2 who developed
symptoms despite BMT and thus underwent CEA. They
showed clear changes in their plaque morphology due
to local complications such as ulceration and intraplaque
hemorrhage. This picture correlates well with other re-
ports,35 conﬁrming our previous observation that certain
features typical of plaque instability may be uninﬂuenced
by statin and antiplatelet therapy and often are responsible
for medically refractory ipsilateral ischemic cerebral
events.36,37 This raises some doubts about the role of sta-
tins in preventing stroke and the inﬂuence of antiplatelet
agents on carotid disease progression, although compli-
ance with cardiovascular prevention differs between clin-
ical trials and daily clinical practice, and this needs to be
taken into account.
The 3- and 5-year cumulative survival in elderly CEA
patients with ASCS was comparable with that of theirmedically treated counterparts, demonstrating that neither
CEA plus BMT nor BMT alone seems to signiﬁcantly
affect such patients’ life expectancy.
Limitation of the study. Our ﬁnding should be inter-
preted bearing the study’s limitations in mind. First,
although the data were collected prospectively, the analysis
was retrospective in nature. Second, the study was deliber-
ately limited to recent years of our clinical experience to
involve a larger number of patients managed with BMT
on the basis of current recommendations.18,38 This may
have led to a selection bias because healthier patients may
be referred for CEA nowadays, although we cannot say for
sure. In addition, the size of the sample is small, the
number of perioperative events nil, and the incidence of
late adverse cerebrovascular ischemic events low, so the
resulting lack of power makes any deﬁnitive statistical
analysis impossible. However, the follow-up was long
enough to underline the importance of our data and to
support our conclusions. Third, as with any chronic treat-
ment, tolerance/compliance decreases over time, so it may
be that not all patients continued to take the recommended
medication regularly. The patients’ adherence to prescribed
smoking bans, close monitoring of hypertension and dia-
betes, and other lifestyle changes are also just as important
as their use of lipid-lowering and antiplatelet drugs, but this
aspect is not easily documented within the conﬁnes of a
retrospective study design.
CONCLUSIONS
This study has suggested that CEA is a safe, effective,
and durable procedure for patients in their 80s with
ASCS. Despite the marked improvement in BMT in recent
years for the prevention of stroke in patients with ASCS, to
assume that it may sufﬁce alone to prevent ipsilateral
adverse ischemic accidents is hazardous and not supported
by randomized data. On the basis of the results of our
observational analysis, CEA plus BMT seems still preferable
to the best medical care alone for preventing stroke in oc-
togenarians with ASCS. Randomized trials on larger sam-
ples and an extended follow-up are needed to compare
CEA with BMT in asymptomatic patients at higher risk
of stroke.
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